# Executive Summary: Paul's Competency Questions Validation

**Date**: 2026-02-02
**Validation Status**: ALL 12 QUESTIONS VALIDATED
**Total CURIEs Resolved**: 100+

## Research Scope

This validation covers 12 competency questions across 4 focus areas, supporting Paul Zamora's research at DMV Petri Dish on drug discovery, tumor biology, and therapeutic approaches.

---

## Focus Area 1: Doxorubicin Research (CQ1-CQ4)

### Summary

Doxorubicin (CHEMBL:53463) is an FDA-approved anthracycline with well-characterized cardiotoxicity mediated by TOP2B inhibition. The NRF2 antioxidant pathway provides protection, and Dexrazoxane is the only FDA-approved cardioprotective agent.

### Key Findings

| CQ | Finding | Confidence |
|----|---------|------------|
| **CQ1** | TOP2B (HGNC:11990) inhibition causes cardiomyopathy (EFO:0000318, score 0.465) | HIGH |
| **CQ2** | ABCB1/P-gp (HGNC:40) mediates efflux; Phase 3 inhibitor trials failed | HIGH |
| **CQ3** | NFE2L2/NRF2 (HGNC:7782) coordinates antioxidant defense via WP:WP408 | HIGH |
| **CQ4** | Dexrazoxane (CHEMBL:1738) FDA-approved; P-gp inhibitors failed translation | HIGH |

### CURIEs

```
Compounds: CHEMBL:53463 (Doxorubicin), CHEMBL:1738 (Dexrazoxane), CHEMBL:348475 (Tariquidar)
Genes: HGNC:11990 (TOP2B), HGNC:40 (ABCB1), HGNC:7782 (NFE2L2), HGNC:11180 (SOD2)
Pathways: WP:WP408 (Oxidative stress), WP:WP1780 (ABC transport)
Diseases: EFO:0000318 (Cardiomyopathy)
```

---

## Focus Area 2: Tumor Microenvironment (CQ5-CQ7)

### Summary

Tumors evade immunity through checkpoint expression (PD-L1, CTLA4), secrete immunosuppressive factors (TGF-β, IL-10), and metastasize via EMT and MMP-mediated ECM degradation.

### Key Findings

| CQ | Finding | Confidence |
|----|---------|------------|
| **CQ5** | CD274/PD-L1 (HGNC:17635) checkpoint; pembrolizumab targets via WP:WP4557 | HIGH |
| **CQ6** | EMT markers: CDH1↓ VIM↑ SNAI1↑; WP:WP3493 coordinates metastasis | HIGH |
| **CQ7** | MMP2/MMP9 (HGNC:7166/7173) degrade ECM; MMP inhibitors failed clinically | HIGH |

### CURIEs

```
Checkpoints: HGNC:17635 (CD274/PD-L1), HGNC:2505 (CTLA4), HGNC:6077 (IDO1)
EMT: HGNC:1748 (CDH1), HGNC:12692 (VIM), HGNC:11128 (SNAI1), HGNC:12428 (TWIST1)
MMPs: HGNC:7166 (MMP2), HGNC:7173 (MMP9), HGNC:7175 (MMP14)
Pathways: WP:WP4557 (PD-L1), WP:WP3493 (EMT), WP:WP2789 (ECM degradation)
```

---

## Focus Area 3: NSCLC / Synthetic Lethality (CQ8-CQ9)

### Summary

NSCLC is driven primarily by KRAS and EGFR mutations. Sotorasib/Adagrasib target KRAS G12C. Synthetic lethality exploits DNA repair deficiencies (BRCA-PARP) with limited lung cancer application to date.

### Key Findings

| CQ | Finding | Confidence |
|----|---------|------------|
| **CQ8** | KRAS G12C: Sotorasib (CHEMBL:4594399), Adagrasib; EGFR: Osimertinib (CHEMBL:3353410) | HIGH |
| **CQ9** | BRCA-PARP synthetic lethality established; KRAS-STK11 combinations emerging | MODERATE |

### CURIEs

```
Targets: HGNC:6407 (KRAS), HGNC:3236 (EGFR), HGNC:1100 (BRCA1), HGNC:270 (PARP1)
Drugs: CHEMBL:4594399 (Sotorasib), CHEMBL:3353410 (Osimertinib), CHEMBL:521686 (Olaparib)
Trials: NCT04989764, NCT05099003 (KRAS inhibitors)
```

---

## Focus Area 4: Method Validation (CQ10-CQ12)

### Summary

The Fuzzy-to-Fact protocol provides a systematic methodology for resolving ambiguous queries to validated CURIEs, with demonstrated scalability for pathway-level analysis.

### Key Findings

| CQ | Finding | Confidence |
|----|---------|------------|
| **CQ10** | 5-phase protocol: ANCHOR → ENRICH → EXPAND → VALIDATE → PERSIST | VALIDATED |
| **CQ11** | TP53 cross-references validated 10/10 across HGNC, UniProt, Ensembl, Entrez | VALIDATED |
| **CQ12** | Complete reasoning chain: Gene → Protein → Interaction → Drug → Trial | VALIDATED |

### Demonstrated

```
Scalability: 50 genes @ ~20s parallel, ~45K tokens
Error handling: UNRESOLVED_ENTITY, ENTITY_NOT_FOUND, RATE_LIMITED
Rate limits: NCBI 3→10 req/s with API key, STRING 1000/day
```

---

## Cross-Cutting Insights

### Translational Gaps

| Preclinical | Clinical | Status |
|-------------|----------|--------|
| P-gp inhibition reverses resistance | Tariquidar Phase 3 terminated | FAILED |
| MMP inhibitors block metastasis | Marimastat trials failed | FAILED |
| Dexrazoxane iron chelation | FDA-approved cardioprotection | SUCCESS |
| KRAS G12C inhibition | Sotorasib FDA-approved | SUCCESS |
| BRCA-PARP synthetic lethality | Olaparib FDA-approved | SUCCESS |

### Knowledge Graph Edges (High Confidence)

```cypher
// Doxorubicin cardiotoxicity
(:Compound {curie: "CHEMBL:53463"})-[:INHIBITS]->(:Gene {curie: "HGNC:11990"})
(:Gene {curie: "HGNC:11990"})-[:ASSOCIATED_WITH {score: 0.465}]->(:Disease {curie: "EFO:0000318"})

// KRAS targeting
(:Gene {curie: "HGNC:6407"})-[:MUTANT_TARGETED_BY]->(:Compound {curie: "CHEMBL:4594399"})

// Immune checkpoint
(:Gene {curie: "HGNC:17635"})-[:TARGETED_BY]->(:Compound {curie: "CHEMBL:1201833"})

// Synthetic lethality
(:Gene {curie: "HGNC:1100"})-[:SYNTHETIC_LETHAL_WITH]->(:Gene {curie: "HGNC:270"})
```

---

## Total CURIEs by Category

| Category | Count | Key Examples |
|----------|-------|--------------|
| Compounds | 15+ | Doxorubicin, Sotorasib, Olaparib, Pembrolizumab |
| Genes | 50+ | TOP2B, KRAS, EGFR, BRCA1, PD-L1, NFE2L2 |
| Proteins | 30+ | P-gp, MMP2, TGF-β, IL-10 |
| Pathways | 12+ | WP:WP408, WP:WP3493, WP:WP4557 |
| Diseases | 8+ | Cardiomyopathy, NSCLC, Breast Cancer |
| Trials | 25+ | Via ClinicalTrials.gov curl |

---

## Next Steps

1. **Graphiti Persistence**: Store all validated entities to graphiti-docker with focus area group_ids
2. **Graph Visualization**: Generate knowledge graph HTML for each focus area
3. **Literature Deep Dive**: Fetch full PubMed article metadata for key citations
4. **Clinical Trial Monitoring**: Set up alerts for trials transitioning phases

---

## Files Generated

```
docs/competency-questions/validation/paul/
├── README.md                    # This navigation file
├── EXECUTIVE-SUMMARY.md         # Consolidated findings (this file)
├── cq1-cardiotoxicity.md        # FA1: Doxorubicin cardiotoxicity
├── cq2-resistance.md            # FA1: Resistance mechanisms
├── cq3-protective-pathways.md   # FA1: NRF2 antioxidant pathway
├── cq4-clinical-correlation.md  # FA1: Preclinical-clinical correlation
├── cq5-immune-evasion.md        # FA2: Immune checkpoint evasion
├── cq6-metastasis.md            # FA2: EMT and metastasis
├── cq7-protease-secretion.md    # FA2: MMP and ECM degradation
├── cq8-nsclc-candidates.md      # FA3: NSCLC drug landscape
├── cq9-synthetic-lethality.md   # FA3: Synthetic lethality approaches
├── cq10-method-steps.md         # FA4: Fuzzy-to-Fact protocol
├── cq11-omix-validation.md      # FA4: Cross-reference validation
└── cq12-reasoning-chain.md      # FA4: Full reasoning demonstration
```

**Total Files**: 14 (12 CQs + README + Executive Summary)
**Total Size**: ~145KB of validated research documentation
